新型治疗慢性丙型肝炎药特拉瑞韦的药理与临床评价进展
摘要
特拉瑞韦是一种可逆的丙型肝炎病毒(HCV)NS3/NS4蛋白酶抑制剂,2011年5月23日获得美国食品药品管理局(FDA)批准与聚乙二醇干扰素α和利巴韦林联合使用用于治疗HCV。本文对特拉瑞韦的药理作用、药动学、临床评价、安全性以及药物相互作用等进行了综述。
出处
《临床合理用药杂志》
2013年第15期5-6,共2页
Chinese Journal of Clinical Rational Drug Use
参考文献13
-
1World Health Organization web site. Initiative for vaccine research. Hepatitis C virus [EB/OL]. Available at: www. who. int/vaccine - research/diseases/viral - cancers/en/index2, html. Accessed April 6, 2010.
-
2Chen SH, Tan SL. Discovery of small - molecule inhibitors of HCV NS3 -4A protease as potential therapeutic agents against HCV infection [J]. Curt Med Chem, 2005, 12 (20) : 2317 -2342.
-
3Flores MV, Strawbridge J, CiarameUa G, et al. HCV - NS3 inhibi- tots: determination of their kinetic parameters and mechanism [J].Biechim Biophys Acta, 2009, 1794 (10): 1441-1448.
-
4De Fruncesco R, Carfi A. Advances in the development of new thera- peutic agents targeting the NS3 -4A sefineprotease or the NSSB RNA - dependent RNA polymerase of the hepatitis C virus [J]. Adv Drug De- liv Rev, 2007, 59 (12) : 1242 -1262.
-
5Vertex Pharmaceuticals. Research findings suggest potent anfiviral activ- ity and favorable in vitro resistance profile for vertex's investigational HCV protease inhibitor VX - 950 [ EB/OL ]. www. vrtx. corn, 27 Oct 2003 Media Release.
-
6Chu HM, Herrmann E, Reesink HW, et al. Pharmacokinetics of VX -950, and its effect on hepatitis C viral dynamics [J]. Hepatology, 2005, 42 ( Suppl 1 ) : 694 - 695.
-
7Perui RB, Almquist SJ, Bym RA, et al. Preclinieal profile of VX - 950, a potent, selective, and orally bioavailableinhibitor of hepatitis C virus NS3 -4A serine protease [J]. Antimicrob Agents Chemother, 2006, 50 (3) : 899 -909.
-
8Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection [J]. Curt Med Chem, 2009, 16 (9): 1115-1121.
-
9Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX - 950, a potent, selective, and orally bioavailable inhibithor of hepatitis C vires NS3 -4A serine protease [J]. Antimlcrob Agents Chemother, 2006, 50 (3): 899-909.
-
10Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection [J]. N Engl J Med, 2011, 364 (25): 2417- 2428.
-
1周云仙,任蔚虹.炎症性肠病患者生存质量评价进展[J].护理与康复,2007,6(10):666-668. 被引量：1
-
2赵荣,彭劲松,黄汉菊,陈维贤.丙型肝炎病毒基因分型检测策略[J].国际检验医学杂志,2012,33(2):191-194. 被引量：4
-
3王宇明,程林.中药抗乙型肝炎病毒/丙型肝炎病毒研究新进展[J].临床肝胆病杂志,2012,28(11):872-876. 被引量：3
-
4阎西艴.钙拮抗剂治疗高血压的药理与临床现状[J].临床医学,1989,9(6):258-261. 被引量：1
-
5崔坡,孔丽,赵素贤.丙型肝炎的直接抗病毒药物[J].临床荟萃,2016,31(7):727-731. 被引量：2
-
6黄建宏,凌文辉,林心,禤彩云,郑通明.白细胞介素17在慢性丙型肝炎患者免疫损伤中的作用[J].国际检验医学杂志,2013,34(21):2819-2820.
-
7东冰,张萍萍,赵培东,靳永胜,徐光华.急性HBV/HCV重叠感染1例报告[J].临床肝胆病杂志,2016,32(8):1580-1581. 被引量：3
-
8李强,黄玉仙,陈良.HCV相关肝硬化抗病毒治疗现状[J].临床肝胆病杂志,2015,31(11):1813-1816. 被引量：4
-
9张雨,成军.HCV相关性脂肪肝[J].临床肝胆病杂志,2015,31(7):1034-1037. 被引量：1
-
10殷霄,文波,谭文杰.增强丙型肝炎病毒DNA疫苗免疫原性的策略[J].临床肝胆病杂志,2011,27(1):32-35.
